Last checked at 26 May 2017 07:00
26 May 2017
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Deltex releases ODMV+ system for veterinary anaesthesia and critical care
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the launch of its first ODM system designed specifically for veterinary use which has generated £15,000 on release from the first sale of a system to a leading continental Europe Veterinary University.
The ODMV+ monitor is based on the CardioQ-ODM+ platform and is accessed via the specially designed K9 probes. These probes are designed for smaller animals such as dogs and cats and allow multiple uses for a period of 30 days, providing an attractive per case billing model for veterinary practices.
Deltex is planning the marketing launch of the new system for the annual meeting of the International Veterinary Emergency and Critical Care Symposium ('IVECCS') in Nashville, Tennessee in September 2017. In the meantime it is promoting the system to existing contacts.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"We are delighted to have made our first sale of the ODMV+ system simultaneously with its release. ODM is ideally suited for use in animals who tend to have high degrees of haemodynamic instability during surgery and in critical care.
"We have a small number of other customers already interested in the system and expect to generate further interest after the market launch at IVECCS at which there will be presentations from a number of experts who have been working with Deltex on developing the ODMV+. Our medium term goal is to develop the veterinary business to a stage where it is sold through specialist distributors."
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman | |
Ewan Phillips, Chief Executive | |
Jonathan Shaw, Group Finance Director | |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Financial Public Relations | |
IFC Advisory | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.